Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

TGen selected to conduct cancer experiments using advanced computer simulations

SAIC-Frederick Inc., under its prime contract with the National Cancer Institute, has named the Translational Genomics Research Institute (TGen) as one of five national centers selected to conduct cancer experiments using advanced computer simulations.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Angiochem to announce clinical study results of ANG1005 drug

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.

8 Oct 2009

Physical activity during adolescence decreases risk of glioma

While little is known about the causes of glioma, researchers at the National Cancer Institute have found that this rare but often deadly form of brain cancer may be linked to early life physical activity and height.

7 Oct 2009

61 institutions awarded grants for cancer research from American Cancer Society

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 new national research and training grants totaling $45,097,000 to 61 institutions nationwide in the second of two grants cycles for 2009. The grants go into effect beginning January 1, 2010.

3 Oct 2009

Immunocellular Therapeutics' pilot study can help in early cancer detection

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Data from this study demonstrated that ICT-109 had a statistically significant ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets.

30 Sep 2009

Titanium dioxide nanoparticles catalyze brain tumor death

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago Medical Center's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to antibodies.

23 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

23 Sep 2009

Multiple Myeloma Research Foundation focuses on effective cancer treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that American figure skating legend and Olympic gold medalist Scott Hamilton will serve as Master of Ceremonies at the 13th Annual MMRF Fall Gala, on Saturday, Oct. 24, 2009, at the Hyatt Regency in Greenwich, Conn.

19 Sep 2009

Cancer Program established to treat young cancer patients

A new partnership of Providence Health & Services, Childrens Hospital Los Angeles and the Childrens Hospital Los Angeles Medical Group has been developed to treat young adults with cancer, providing diagnostics and treatment for a group that nationwide falls in a gap between adult and pediatric health care.

16 Sep 2009

Vitro Diagnostics' novel stem cell technology for cancer treatment

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

10 Sep 2009

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

Nanobio hybrids for brain cancer therapy

In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. The study is scheduled for the Sept. 9 issue of ACS' Nano Letters, a monthly journal.

10 Sep 2009

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

Hospital executives weigh benefits, risks of health reform

Hospital executives are balancing their hopes that expanded coverage will provide a windfall for facilities now burdened by uncompensated care with their fears that government intervention, such as the possible creation of a public insurance option, could cut into their revenues, the Atlanta Journal-Constitution reports.

10 Sep 2009

Protox Therapeutics to present TRIUMPH clinical study update

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference.

9 Sep 2009

Senators return to full plate, featuring health bills

"The focus on health care as Congress reconvenes Tuesday after its monthlong recess is nearly all-consuming," The Associated Press reports. "At stake, beyond the future of health care, is an accomplishment Democrats need to convince voters they deserve to remain in power." Financial legislation, consumer protections and clean energy are also still on the table in the Senate (Abrams, 9/8).

9 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Scientists solve the mystery of zonulin's identity

It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes.

8 Sep 2009

Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier

Earlier this year, researchers at the University of Washington reported that they had developed a toxin-nanoparticle combination that inhibits brain cancer invasion when added to tumor cells growing in culture.

7 Sep 2009